Substituted indole compounds

US11739098B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Alaric J. Dyckman · Lawrenceville, US
• Dharmpal S. Dodd · Princeton, US
• Christopher P. Mussari · Princeton, US
• Trevor C. Sherwood · Plainsboro, US
• John L. Gilmore · Yardley, US
• Tasir Shamsul Haque · Yardley, US
• Brian K. Whiteley · Lebanon, US
• David R. Tortolani · Skillman, US
• Shoshana L. Posy · Highland Park, US
• John E. Macor · Guilford, US
• Louis J. Lombardo · Montgomery, US
• Ramesh Kumar Sistla · Bengaluru, IN
• Anupama Kandhi Ramachandra Reddy · Chitradurga, IN
• Subramanya Hegde · Kanchinakote, IN
• Laxman Pasunoori · Warangal, IN
• Sreekantha Ratna Kumar · Bengaluru, IN

Key dates

• Filing date: Mar 21, 2022
• Grant date: Aug 29, 2023
• Expiry date: Mar 21, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.